ArticleMikrochimica acta2023
Aptasensor for ovarian cancer biomarker detection using nanostructured gold electrodes.
Article in Mikrochimica acta, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Femtogram-level VEGF detection via PEG-directed gold nanostructured electrochemical immunosensor.Scientific reports · 2025Article
- Modern Emerging Biosensing Methodologies for the Early Diagnosis and Screening of Ovarian Cancer.Biosensors · 2025Review
- Controlled electrochemical fabrication of large and stable gold nanorods with reduced cytotoxicity.Scientific reports · 2025Article
- Gold nanoparticles in the diagnosis and treatment of ovarian and cervical cancers: a comprehensive understanding.Frontiers in oncology · 2025Review
- Comprehensive analysis of electrochemical biosensors for early ovarian cancer detection.RSC advances · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of an electrochemical aptasensor for the detection of CA125 as an ovarian cancer biomarker using gold nanostructures (GNs) modified electrodes is reported. The GNs were deposited on the surface of fluorine-doped tin oxide electrodes using a simple electrochemical method and the effects of pH and surfactant concentration on the topography and electrochemical properties of the resulting GNs modified electrodes were investigated. The electrodes were characterized using field-emission scanning electron microscopy and X-ray diffraction, cyclic voltammetry, and electrochemical impedance spectroscopy. The best electrode, in terms of the uniformity of the deposited GNs and the increase in electroactive surface area, was used for development of an aptasensor for CA125 tumor marker detection in human serum. Signal amplification was done by using aptamer-conjugated gold nanorods resulting in the detection limit of 2.6 U/ml and a linear range of 10 to 800 U/ml. The results showed that without the need for expensive antibodies, the developed aptasensor could specifically measure the clinically relevant concentrations of the tumor marker in human serum.
Indexed as
Identifiers
38040925What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.